(NIH) TScan Therapeutics has raised a cool $100 million in a series C to start 2021 on the positive notes it rang throughout 2020. Boston area-based TScan launched in July 2019 with the goal of identifying new targets for T-cell therapies in both blood cancers and solid tumors. It started off with $48 million and later inked a collaboration with its Big Pharma backer Novartis for research into kidney cancer. Then, late last year, it took aim at COVID-19—turning its genome-based, high-throughput discovery platform for parsing T-cell receptors (TCRs) toward the coronavirus pandemic and how those immune cells react—and inked a licensing agreement with Qiagen.